Clinical Trial

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Study acronym: MIDAS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-11-05; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2025-05-20
Trial Details
NCT Number NCT06679855
Lead Sponsor NICHD Neonatal Research Network
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Post-ligation Cardiac Syndrome
Enrollment 316 participants
Start Date 2025-06-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01